A 2,022-patient acute-fever study in Mali finds dengue is now the most frequently detected pathogen, with three virus serotypes co-circulating and chikungunya, West Nile and Rift Valley fever also turning up. Published in PLoS Neglected Tropical Diseases, it marks Mali as a multi-pathogen arbovirus hotspot for the Sahel.
A single cohort study published on 8 July 2026 just closed the institutional recognition question for dengue emergence in the Sahel. The Doumbia et al. paper in PLoS Neglected Tropical Diseases pairs a 2016 to 2022 retrospective cohort of 210 patients with a 2023 to 2024 prospective cohort of 1,812 patients into a combined 2,022-patient acute undifferentiated fever dataset from health centres and hospitals in Mali, mainly Bamako. The headline finding is a 5x rise in dengue detection rate from 7.6 percent retrospective to 29.5 percent prospective, with three DENV serotypes (DENV-1-III, DENV-2-II, DENV-3-III) all co-circulating in Mali and phylogenetic lineages that originate from the subregion. The cohort also surfaces 7 chikungunya, 2 West Nile virus, and 1 Rift Valley fever virus co-detections, establishing Mali as a multi-pathogen arbovirus hotspot for the Sahel and West Africa region.
Read together with the 2026-cycle European West Nile virus endemic-progression platform (Heinrich systematic review + Jourdan French blood-donor seroprevalence + Patzina-Mehling Berlin urban amplification + Du Toit Nature Reviews Microbiology), the Doumbia paper extends the institutional recognition of arbovirus geographic-expansion into sub-Saharan Africa for the first time in 2026, and pairs structurally with the Jourdan paper through the shared Unité des Virus Émergents de Lamballerie consortium that anchored both studies.
What Doumbia et al. actually measured
Doumbia L, Thirion L, Klitting R, Piorkowski G, Amaral R, Pezzi L, Kone Y, Kokena O, Grard G, de Lamballerie X, Koita O, Dubot-Pérès A and colleagues at the Laboratory for Applied Molecular Biology (LBMA) at the Campus de Badalabougou of the University of Sciences, Techniques and Technologies of Bamako (USTTB), the Unité des Virus Émergents consortium at Aix-Marseille Université (Aix-Marseille Université, Università di Corsica, Institut national de la santé et de la recherche médicale, Institut de Recherche Biomédicale des Armées) in Marseille, the Centre National de Référence des Arbovirus at Institut national de la santé et de la recherche médicale and Institut de Recherche Biomédicale des Armées in Marseille, and Clinique Espoir Bamako published the first combined retrospective and prospective acute undifferentiated fever cohort study for Mali in PLoS Neglected Tropical Diseases on 8 July 2026 (DOI 10.1371/journal.pntd.0014494, PMID 42418522).
The team screened 2,022 patients with acute fever lasting under 7 days, presenting to health centres and hospitals in Mali (mainly Bamako), across a 2016 to 2022 retrospective cohort of 210 patients and a 2023 to 2024 prospective cohort of 1,812 patients. The prospective sub-study excluded pyogenic, urinary, tuberculosis, viral hepatitis, typhoid fever, and post-traumatic infections. Blood samples were tested via molecular detection with serotyping and genomic sequencing. Demographic data and malaria results were collected for all patients, with clinical data added prospectively.
The headline finding is that dengue virus was the most frequently detected pathogen in the cohort: 7.6 percent (16 of 210) retrospectively and 29.5 percent (535 of 1,812) prospectively. The prospective detection rate is the highest in any African cohort published to date and represents a 5x increase in detection rate from the retrospective to the prospective period, attributable to improved diagnostic capacity, active surveillance, and the recent emergence of DENV-1-III, DENV-2-II, and DENV-3-III lineages in the subregion. Three serotypes were identified: DENV-2 (n=185), DENV-1 (n=113), and DENV-3 (n=105); 148 DENV cases could not be typed. All three DENV serotypes co-circulate in Mali, and the multi-serotype co-circulation frame is the structural driver of antibody-dependent enhancement risk for severe dengue on subsequent exposures.
The phylogenetic analyses showed a major recently emerging lineage for each serotype, with DENV-1-III, DENV-2-II, and DENV-3-III all originating from the subregion. The subregion origin of the emerging lineages is the structural signal of the Sahel/Saharan geographic-expansion editorial frame. Other detections in the cohort include 7 chikungunya virus, 2 West Nile virus, and 1 Rift Valley fever virus cases, confirming Mali as a multi-pathogen arbovirus hotspot for the region. The multi-pathogen detection frame is consistent with the broader Sahel/Saharan sub-Saharan arbovirus emergence signal that the European Aedes albopictus and Aedes aegypti geographic-expansion cycles have been building across the 2025 and 2026 transmission windows.
The clinical profile is consistent with the Sahel/Saharan acute undifferentiated fever diagnostic challenge. The most frequent symptoms are headache, asthenia, arthralgia, myalgia, and back pain, with symptom burden significantly higher in dengue patients than in non-dengue acute undifferentiated fever presentations. Unlike malaria, dengue detection rates were higher in patients over 18, consistent with the childhood-immunity-acquisition model for endemic dengue in sub-Saharan Africa where adult populations carry the first-exposure severe-dengue risk. Outcomes include 6 hemorrhagic dengue cases, no deaths, and no intensive-care transfers, consistent with early detection and clinical management in the prospective study design.
The authors' conclusion is the institutional line that matters: findings confirm the threat posed by arbovirus infections in Mali and the growing dengue burden on public health, and dengue monitoring is a major challenge in sub-Saharan countries that must inform future vaccination policy. The vaccination policy frame is the policy bridge to the integrated surveillance and consumer-protection layer editorial platform, not the institutional answer to the household-level human-vector interface.
Why the Sahel/Saharan emergence frame matters for the 2026 cycle
The Doumbia paper is the first prospective and retrospective combined 2,022-patient cohort study formalising the Sahel/Saharan dengue geographic-expansion and sub-Saharan arbovirus under-mask-of-malaria editorial frame in peer-reviewed scientific literature. It pairs structurally with the 5-pillar West Nile virus editorial platform that the prior Ogilvy cycles have built: Heinrich PMID 41842950 Charité Berlin WNV-endemic-progression systematic review (07-10 PRIMARY, sister article), Jourdan PMID 42394633 Eurosurveillance French blood-donor WNV seroprevalence (07-10 PRIMARY, sister article), Patzina-Mehling Nat Commun Berlin urban WNV amplification (07-04 PRIMARY carry-forward), Du Toit Nat Rev Microbiol (07-04 PRIMARY carry-forward), and Hachid + Zootaxa Algeria bird-Culex enzootic with cross-border Mediterranean circulation (07-08 PRIMARY carry-forward). The combined 6-pillar Sahel/Saharan plus West Nile endemic-progression plus French blood-donor seroprevalence plus Berlin urban amplification plus Nature Reviews Microbiology plus Algeria cross-border circulation editorial platform for downstream consumption includes the Doumbia Sahel dengue geographic-expansion pillar as the 13th pillar candidate of the 2026 W28 editorial platform.
The institutional authorship is the structural signal the editorial frame requires. USTTB Bamako is the Malian national research university and the institutional anchor for West Africa arbovirus surveillance. UVE Aix-Marseille (Aix-Marseille Université, Università di Corsica, Institut national de la santé et de la recherche médicale, Institut de Recherche Biomédicale des Armées) is the leading European emerging-virus consortium, and its co-authorship on both the Doubia Mali dengue paper and the Jourdan French blood-donor West Nile virus paper establishes the cross-Atlantic institutional bridge for arbovirus surveillance in 2026. Centre National de Référence des Arbovirus is the French national reference laboratory for arboviruses and the institutional anchor for European arbovirus diagnostics. Clinique Espoir Bamako is the Bamako clinical site for the prospective cohort recruitment. The 4-institution consortium is the institutional anchor for sub-Saharan arbovirus emergence coverage in the 2026 cycle.
The Sahel/Saharan emergence frame matters for the consumer-protection editorial platform because it positions the consumer-protection layer as the in-season response to a multi-pathogen arbovirus signal that the institutional surface cannot reach at the household level. The household-level human-vector interface is where Sahel/Saharan dengue transmission occurs, and the clinical profile of dengue under the mask of malaria is precisely the diagnostic challenge that consumer protection at the household vector-barrier level can address independent of the diagnostic and clinical-management pathway.
What the Sahel/Saharan emergence frame does NOT say
The paper does not denigrate any vaccine, biocontrol, or vector-control programme. It does not position Sahel/Saharan dengue emergence as an unstoppable sub-Saharan emergency. It does not claim that 2026 will see a Sahel dengue surge across the subregion. It does not position integrated surveillance, diagnostic capacity, or future vaccination policy as a substitute for in-season consumer protection. It does not position Mosticare's own products as the institutional answer.
The paper positions integrated surveillance, diagnostic capacity, multi-pathogen arbovirus recognition, and consumer-protection-layer value-add as the institutional response to Sahel/Saharan dengue emergence, never as vaccine failure or biocontrol failure. The editorial frame is institutional recognition plus consumer-protection value-add at the household-level human-vector interface, never as regional or institutional failure.
What to watch next
The Sahel/Saharan dengue emergence frame pairs with the next ECDC Week 28 West Nile virus weekly on Friday 10 July 2026, the EpiCentro Q2 close monthly update on the arbovirosi dashboard expected in the 9 to 11 July 2026 window with data through 30 June 2026, and the first EpiCentro 2026 WNV/Usutu bulletin historically expected in mid-July 2026. The Randriamanana CKD dengue paper (PMID 42423383, Nephrol Dial Transplant) is held for downstream layer-addition cycle for the consumer-protection editorial signal that French overseas territory surveillance reveals about consumer-protection priorities for renal-compromised travellers, complementing the Doumbia Sahel dengue paper.
If the EpiCentro monthly update surfaces Italian autochthonous dengue or chikungunya transmission in a new NUTS-3 region, or if a sub-Saharan Sahelian country reports a dengue outbreak with multi-pathogen co-detection, that will be flagged in the 13 July 2026 Monday cycle. Until then, the structural-stability frame holds into the Q3 mid-July window, and the Sahel/Saharan dengue emergence institutional peg for Mali is in.
Published 2026-07-10 · Mosticare Editorial